Cargando…

Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease

In neurons, mitochondria serve a wide variety of processes that are integral to their function and survival. It is, therefore, not surprising that evidence of mitochondrial dysfunction is observed across numerous neurodegenerative diseases. Alzheimer's disease and Parkinson's disease are t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoekstra, Jake G, Montine, Kathleen S, Zhang, Jing, Montine, Thomas J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226310/ https://www.ncbi.nlm.nih.gov/pubmed/21722346 http://dx.doi.org/10.1186/alzrt83

Ejemplares similares

Precision medicine: Clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases
por: Montine, Thomas J., et al.
Publicado: (2015)

Single-cell peripheral immunoprofiling of Alzheimer’s and Parkinson’s diseases
por: Phongpreecha, Thanaphong, et al.
Publicado: (2020)

Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer’s and Parkinson’s diseases
por: Corces, M. Ryan, et al.
Publicado: (2020)

Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo
por: Milatovic, Dejan, et al.
Publicado: (2004)

Traumatic brain injury may not increase the risk of Alzheimer disease
por: Weiner, Michael W., et al.
Publicado: (2017)

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
por: Lesniak, Robert K., et al.
Publicado: (2022)

Unveiling Resilience to Alzheimer’s Disease: Insights From Brain Regional Proteomic Markers
por: Huang, Zhi, et al.
Publicado: (2023)

Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice
por: Maezawa, Izumi, et al.
Publicado: (2006)

Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer’s disease
por: Huang, Zhi, et al.
Publicado: (2023)

Resting-State Cerebello-Cortical Dysfunction in Parkinson's Disease
por: Palmer, William C., et al.
Publicado: (2021)

Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer’s Disease Pathology(1)
por: Ryman, Sephira G., et al.
Publicado: (2021)

AI-enabled in silico immunohistochemical characterization for Alzheimer's disease
por: He, Bryan, et al.
Publicado: (2022)

Attention Network Test fMRI data for participants with Parkinson’s disease and healthy elderly
por: Day, Trevor K. M., et al.
Publicado: (2019)

Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease
por: Tapias, Victor, et al.
Publicado: (2023)

Multivariate prediction of dementia in Parkinson’s disease
por: Phongpreecha, Thanaphong, et al.
Publicado: (2020)

Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?
por: Tropea, Thomas F., et al.
Publicado: (2021)

Prostaglandin E(2 )receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α-synuclein
por: Jin, Jinghua, et al.
Publicado: (2007)

Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation
por: Cudaback, Eiron, et al.
Publicado: (2012)

Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity
por: Maezawa, Izumi, et al.
Publicado: (2006)

Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease
por: Higginbotham, Lenora, et al.
Publicado: (2019)

Predictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
por: Hwangbo, Nathan, et al.
Publicado: (2022)

Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE
por: Phongpreecha, Thanaphong, et al.
Publicado: (2021)

Whole genome deconvolution unveils Alzheimer’s resilient epigenetic signature
por: Berson, Eloise, et al.
Publicado: (2023)

Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease
por: Martini, Douglas N., et al.
Publicado: (2020)

Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer’s disease and Parkinson’s disease
por: Ganguly, Gargi, et al.
Publicado: (2017)

Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson’s Disease
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease
por: Onyango, Isaac G.
Publicado: (2018)

Mitochondrial dysfunction: A notable contributor to the progression of Alzheimer's and Parkinson's disease
por: Olagunju, Abolaji Samson, et al.
Publicado: (2023)

Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy Body and Alzheimer’s Disease
por: Postupna, Nadia O., et al.
Publicado: (2014)

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
por: Henrich, Martin T., et al.
Publicado: (2023)

Mitochondrial complex I as a therapeutic target for Alzheimer's disease
por: Trushina, Eugenia, et al.
Publicado: (2022)

Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention
por: Lim, Ji Woong, et al.
Publicado: (2020)

Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures
por: Kim, Hojoong M., et al.
Publicado: (2019)

DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease
por: Lin, Xiangmin, et al.
Publicado: (2012)

Mitochondrially-Targeted Therapeutic Strategies for Alzheimer’s Disease
por: Onyango, Isaac G., et al.
Publicado: (2021)

Methylation differences in Alzheimer’s disease neuropathologic change in the aged human brain
por: Lang, Anna-Lena, et al.
Publicado: (2022)

Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease
por: Xie, Anmu, et al.
Publicado: (2014)

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
por: Nowell, Joseph, et al.
Publicado: (2022)

Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer’s Disease
por: Villavicencio Tejo, Francisca, et al.
Publicado: (2021)

Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope
por: Nabi, Showkat Ul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dlnv0hgqgq8qg3u4552455ft7j